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Abstract 41 
Background  A meningococcal group A conjugate vaccine, PsA-TT (MenAfriVac), was developed with the support of 42 
the Meningitis Vaccine Project.  Around 280 million individuals aged 1 to 29 years have been immunised across the 43 
African meningitis belt.  We analysed the kinetics of vaccine-induced antibody response and assessed the possible 44 
implications for duration of protection. 45 
Methods  We obtained data from longitudinal studies of antibody responses in 193 children aged 12 to 23 months, 46 
and 605 participants aged 2 to 29 years following MenAfriVac vaccination.  Antibodies were measured using two 47 
methods: group A serum bactericidal antibody (SBA) assay and group A-specific IgG ELISA.  Data on antibody 48 
responses were analysed using a mixed-effects statistical model accounting for the mean response and variation in 49 
patterns of antibody kinetics.  50 
Findings  In children age 12 to 23 months, the reduction in MenAfriVac-induced antibody levels assessed by SBA 51 
titers had two phases; with 97·0% (95% credible interval (CrI): 95·1%, 98·3%) of the response being short-lived and 52 
decaying within the first 6 months, and the remainder being long-lived and decaying with a half-life of 7·4 (95% CrI: 53 
2·8, 41·3) years.  Antibody levels assessed by SBA titers in participants aged 2 to 29 were more persistent, with 54 
95·0% (95% CrI: 85·7%, 98·1%) of the response being short-lived, and the long-lived phase decaying with a half-life of 55 
16·5 (95% CrI: 7·7, 39·1) years.  Greater pre-vaccination antibody levels were associated with greater 56 
immunogenicity following vaccination, as well as greater antibody persistence.  There is no strong evidence base for 57 
a correlate of protection against infection with Neisseria meningitidis serogroup A (NmA).  Despite rapid antibody 58 
declines in the first phase, antibodies in the second phase persisted at SBA titers greater than 128.  Based on this 59 
assumed relationship between SBA titer and protection, we predict that 20 years after vaccination with a single dose 60 
of MenAfriVac, vaccine efficacy will be 52% (95% CrI: 29%, 73%) in children vaccinated at age 12 to 23 months, and 61 
70% (95% CrI: 60%, 79%) in participants vaccinated at age 2 to 29 years.  62 
Interpretation  The introduction of MenAfriVac in mass campaigns has been followed by substantial reductions in 63 
NmA cases.  Routine immunisation with EPI is now being rolled out.  Careful monitoring is required to ensure the 64 
continued success of MenAfriVac, and future policy can be guided by understanding of the duration of protection 65 
provided here. 66 
Funding  Meningitis Vaccine Project and Institut Pasteur. 67 
 68 
 69 
 70 
 71 
 72 
 73 
 74 
Research in context 75 
Evidence before this study 76 
We searched PubMed on July 10, 2018, for studies on the immunogenicity of the MenAfriVac Neisseria meningitidis 77 
serogroup A vaccine using the MeSH terms (“MenAfriVac” OR “PsA-TT”) and (“immunogenicity” OR “antibody”).  We 78 
identified 18 reports.  11 of these studies investigated the immunogenicity of MenAfriVac within 1-2 years of 79 
vaccination.  2 studies demonstrated that antibody responses following MenAfriVac persist for time periods of up to 80 
5 years.  81 
Added value of this study 82 
This study builds on previous data by using a statistical model to predict antibody levels up to 20 years following 83 
vaccination and assess the implications for the duration of vaccine-induced protection with robust quantification of 84 
uncertainty.  The decay of antibody levels after vaccination can be described by a bi-phasic exponential relationship 85 
with a phase of rapid decay in the first 6 months, followed by a second slower phase of decay.  Importantly, in this 86 
second slowly decaying phase, antibody levels are predicted to remain above the assumed threshold for protection 87 
for substantial periods of time such that the estimated efficacy in children aged 12 to 23 months is 52% (95% 88 
credible interval (CrI): 29%, 73%) after 20 years, and the estimated efficacy in individuals aged 2 to 29 years is 70% 89 
(95% CrI: 60%, 79%) after 20 years. 90 
Implications of all the available evidence 91 
MenAfriVac has been developed, tested and licensed on the basis of safety and immunogenicity data.  Since 2010 92 
around 280 million individuals have received this vaccine, leading to the widespread disappearance of Group A 93 
meningococcal carriage and disease.  The estimates of long-term duration of immunity presented here provide an 94 
evidence base to assess how ongoing and future vaccination strategies will contribute to the maintenance of 95 
population-level immunity over the next 20 years. 96 
 97 
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Introduction 108 
Countries in the African meningitis belt, a region south of the Sahara stretching from Senegal to Ethiopia, have been 109 
subjected to frequent and large epidemics of meningococcal meningitis for more than a century1.  Incidence rates 110 
during epidemics often exceed 500 cases per 100,000 population, with mortality rates of invasive meningococcal 111 
disease of 10% to 15%2.  Neisseria meningitidis serogroup A (NmA) has been responsible for the majority of 112 
epidemics observed in this region, although epidemics due to other serogroups have been recorded3.  113 
In response to these public health needs, a group A meningococcal polysaccharide-tetanus toxoid conjugate vaccine 114 
(PsA-TT; MenAfriVac) has been developed by the Meningitis Vaccine Project (MVP) and the Serum Institute of India 115 
Ltd.4.  MenAfriVac has been delivered to countries in the African meningitis belt through mass vaccination campaigns 116 
of people 1-29 years of age, and countries are now introducing it into their Expanded Programme on Immunization 117 
(EPI) schedules targeting children aged 9-18 months5.   118 
There is limited evidence on the association between antibody levels and vaccine efficacy, with the only established 119 
correlate of protection being group A-specific IgG antibodies ≥2 μg/mL6,7, with no evidence from Africa.  120 
Observational studies of natural immunity have not detected associations between antibody levels and NmA 121 
meningitis incidence8, as reported by the classic studies of Goldschneider et al7.  Despite this, MenAfriVac was 122 
licensed on the basis of safety and immunogenicity data9, with data on effectiveness being collected only after 123 
largescale MenAfriVac campaigns3,10.  Ongoing surveillance efforts have not identified cases of NmA meningococcal 124 
disease in individuals vaccinated with MenAfriVac11.   125 
Increased coverage of MenAfriVac vaccination will lead to higher levels of vaccine-induced immunity in target 126 
populations12, however there is an important need to understand how immunity wanes over time, and to assess the 127 
implications for future population-level protection.  Addressing this key knowledge gap will aid the WHO’s Strategic 128 
Advisory Group of Experts (SAGE) on Immunization to provide guidance on the implementation of mass vaccination 129 
campaigns or routine EPI to ensure the maintenance of population-level immunity.  Although it is known that 130 
antibody responses induced by MenAfriVac decay over time13,14, the duration of vaccine-induced immunity has yet 131 
to be determined15.  Immunogenicity data was central to the recommendation for MenAfriVac licensure, and can 132 
also play a central role in providing initial estimates of the duration of vaccine-induced immunity.  Affordable 133 
multivalent meningococcal vaccines are also being developed, to offer broader protection against groups CWYX in 134 
addition to A16. Investment in these vaccines is currently being considered by Gavi, the Vaccine Alliance and 135 
immunogenicity will again be an important factor.  136 
Here, we analyse longitudinal data on antibody responses using a statistical model of antibody kinetics to investigate 137 
the persistence of antibody responses, and assess the implications for duration of protection.  138 
 139 
 140 
 141 
 142 
Methods  143 
Data 144 
Individual-level data on epidemiological covariates and immunological measurements from two randomized 145 
controlled trials of the MenAfriVac vaccine9 were obtained following a request to MVP’s Access Program.  Data were 146 
not available from participants in trial arms receiving the reference polysaccharide vaccine (PsACWY), or from the 147 
subset of samples taken greater than 4 years after vaccination.   148 
Full details of the PsA-TT-002 study have been reported elsewhere9,13.  In brief, healthy Malian and Gambian children 149 
aged between 12 and 23 months, fully immunized according to the local EPI schedule, were recruited to receive 150 
primary vaccination of either MenAfriVac (10 μg), PsACWY, or Haemophilus influenzae type b vaccine (Hib-TT).  151 
Children were further randomised to receive a second vaccine dose 10 months later.  Blood samples were obtained 152 
prior to primary vaccination; 4 weeks after primary vaccination; prior to secondary vaccination; 1 and 4 weeks after 153 
secondary vaccination; and approximately 1 and 2 years after primary vaccination.  Further samples from a subset of 154 
individuals were taken 5 years after primary vaccination.  The 5 year follow-up data were not directly incorporated in 155 
this analysis, but geometric mean values were used to validate model predictions.  The data are summarised in Table 156 
1 and Supplementary Figure 1.  157 
 158 
Full details of the PsA-TT-003 study have been reported elsewhere9,14.  In brief, healthy Malian, Gambian and 159 
Senegalese participants aged 2-29 years were recruited and randomized to receive either MenAfriVac or PsACWY.  160 
Blood samples were obtained at baseline, 1 month, 6 months and 1 year after primary vaccination.  Further samples 161 
from a subset of individuals were taken 4 years after primary vaccination.  The 4 year follow-up data were not 162 
directly incorporated in this analysis, but geometric mean values were used to validate model predictions.    The data 163 
are summarised in Table 1 and Supplementary Figure 2. 164 
 165 
Table 1 here 166 
 167 
Immunogenicity 168 
Immunogenicity was assessed using two different assays; firstly, with a serum bactericidal antibody (SBA) assay using 169 
the group A target strain F8238 with baby rabbit complement17; and secondly with MenA-specific immunoglobulin G 170 
(IgG) enzyme-linked immunosorbent assay (ELISA).  SBA titers were measured at the Vaccine Evaluation Unit of the 171 
Health Protection Agency (now Public Health England), Manchester, UK; and the ELISA was performed at the Centers 172 
for Disease Control and Prevention (CDC), Atlanta, Georgia.  We refer to antibody levels as measured values from 173 
either of these assays. 174 
 175 
 176 
Statistical analysis 177 
The effects of several covariates on antibody responses, measured in continuous log values, following primary or 178 
secondary vaccination with MenAfriVac were assessed using linear regression models.  The covariates were age in 179 
years, trial, country, sex, height, weight and measurement of antibody response prior to vaccination. The effects of 180 
these covariates on the percentage reduction in antibody responses 1 year following vaccination were assessed 181 
using logistic regression models.  Regression models were applied separately to antibody levels measured using the 182 
IgG ELISA and SBA assays. 183 
 184 
Antibody kinetics 185 
Exposure of the immune system to vaccine antigens stimulates the generation of memory B cells which subsequently 186 
differentiate into antibody secreting cells (ASCs)18.  ASCs generate IgG molecules responsible for vaccine-induced 187 
immunity, and are composed of two populations: one short-lived responsible for the rapid generation of antibodies, 188 
and one long-lived responsible for humoral immunity long after vaccination or initial infection18.  This 189 
immunologically based model has been used to describe antibody kinetics following malaria infection19, pertussis 190 
vaccination20, human papillomavirus vaccination, and hepatitis A vaccination21.  These mathematical models were 191 
adapted to account for the changing antibody response over time following MenAfriVac vaccination.  Primary 192 
vaccination is assumed to induce proliferation of populations of ASCs of size β in a rapid boost.  A proportion ρ of 193 
ASCs are assumed to be short-lived with half-life ds and a proportion 1 – ρ long-lived with half-life dl.  ASCs are 194 
assumed to generate IgG molecules at a constant rate which decay with half-life da.  The antibody response at time t 195 
after primary vaccination can be modelled as: 196 
    0 1
s a l a
l
r t r t r t r t
r t
a s a l
e e e e
Ab t Ab e
r r r r
  
   
       
  
  197 
This equation is valid for antibody responses measured with either assay.  Ab0 is the baseline antibody response prior 198 
to primary vaccination.  Decay rates are calculated from half-lives as follows: rl = loge(2)/dl; rc = loge(2)/dc; and ra = 199 
loge(2)/da.  Some participants in the PsA-TT-002 study received secondary vaccination with MenAfriVac after 10 200 
months.  The antibody response following this second dose are modelled using the same equation as above.  The 201 
model does not account for the role of natural exposure to NmA.  202 
We refer to the first short-lived phase of the response as the IgG molecules generated by short-lived ASCs, and the 203 
second long-lived phase of the response as the IgG molecules generated by long-lived ASCs.  There is not a strong 204 
evidence base for the dose-response relationship between measured antibody responses following vaccination 205 
against N. meningitidis and vaccine efficacy15.  We utilise a flexible functional form22 to investigate a range of 206 
possible relationships: 207 
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where Abprot is the threshold SBA titre required for protection, and α is a shape parameter. 209 
The model for antibody kinetics was fitted separately to data measured from the two assays, and from the two 210 
studies.  A mixed-effects framework was used allowing for characterisation of the kinetics within each individual, 211 
whilst also describing the population-level patterns.  Importantly, on the population level both the mean and 212 
variation in antibody kinetics are accounted for.  The models were fitted in a Bayesian framework utilising Markov 213 
Chain Monte Carlo (MCMC) with informative priors (described in Supplementary Table 4).  214 
 215 
Role of the funding source 216 
Primary data collection was funded by the MVP through a grant from the Bill and Melinda Gates Foundation.  217 
Funding for this secondary analysis was provided by Institut Pasteur.  The sponsors had no role in the design of the 218 
analysis, interpreting the data, or writing this report.  The corresponding author had full access to all the data in the 219 
study and had final responsibility for the decision to submit for publication. 220 
 221 
Results  222 
Immunogenicity following vaccination 223 
Antibody levels measured via SBA titer and group A-specific IgG ELISA were significantly correlated (Pearson’s r = 224 
0·58; p < 0·0001), with a linear relationship on a log-log scale for measurements from post-vaccination samples, but 225 
not from pre-vaccination samples (Supplementary Figure 3), replicating findings reported elsewhere15.  Notably, 226 
different relationships were observed for samples from the PsA-TT-002 and PsA-TT-003 studies, with participants in 227 
the PsA-TT-003 study having substantially higher group A-specific IgG ELISA levels at equal SBA titers. 228 
The dependence of log antibody responses after vaccination on a number of covariates was assessed using linear 229 
regression (Supplementary Table 3), with univariate relationships shown in Supplementary Figure 4.  The results 230 
from this analysis of pooled data were in agreement with findings from the component data sets23.  In the PsA-TT-231 
002 study of children aged 12-23 months, for each extra month of age there was a 9% increase in SBA titers (p = 232 
0·001).  However, in the PsA-TT-003 study of participants aged 2-29 years, for each extra year of age there was a 2% 233 
decrease in SBA titers (p = 0·0009).  High baseline log10 SBA titers were associated with higher log10 SBA titers after 234 
vaccination (p < 0·0001).  When antibody levels were measured by ELISA, there were no significant associations 235 
between age and group A-specific IgG ELISA level following vaccination.  Antibody levels in males were 18% lower 236 
than in females (p = 0·002).  Group A-specific IgG ELISA levels at baseline were significantly associated with higher 237 
levels following primary vaccination (p < 0·0001). 238 
 239 
Antibody kinetics 240 
In both the PsA-TT-002 and PsA-TT-003 studies, the change in antibody response over time was described using a bi-241 
phasic exponential model of decay.  Figure 1A-H shows a comparison of the model predicted antibody kinetics with 242 
data on SBA titers and IgG ELISA levels from a representative subset of 8/797 individuals.  A number of distinctive 243 
patterns are evident: (i) antibody responses induced by MenAfriVac decay rapidly in the first 6 months, after which 244 
the remaining antibodies decay at a slower rate; (ii) in most individuals the initial decay of IgG ELISA levels is more 245 
rapid than the decay of SBA titers; (iii) Hib-TT vaccination causes boosting in SBA titers but not IgG ELISA levels; (iv) 246 
there is substantial variation in the observed antibody kinetics, for example individual G002_3 (Figure 1B) did not 247 
sustain a long-lived antibody response as measured by SBA titer.  Figure 1I-L shows the geometric mean and range of 248 
antibody responses observed in the study population.  The model predicted geometric mean antibody responses 249 
were in agreement with the data from samples at 4 years follow-up in the PsA-TT-003 study, but slightly under-250 
predict the data at 5 years follow-up in the PsA-TT-002 study.  As these data were not used to calibrate the model, 251 
this provides some support for the ability of the model to predict long-term antibody responses.    Figure 1M-P 252 
shows the proportion of individuals predicted to have antibody responses greater than a range of thresholds over 253 
the first 5 years of follow-up. 254 
 255 
The estimated parameters describing the antibody kinetics are presented in Table 2.  In the PsA-TT-002 study, 256 
primary vaccination with MenAfriVac is assumed to induce ASCs that generate antibodies causing bactericidal 257 
activity.  For measurements from the SBA assay all ASCs are assumed to secrete IgG molecules which decay with an 258 
estimated half-life of 15·4 (95% Credible Interval (CrI): 12·0, 20·0) days.  The short-lived phase is estimated to 259 
constitute 97·0% (95% CrI: 95·1%, 98·3%) of the response with a median half-life of short-lived ASCs of 3·5 (95% CrI: 260 
2·1, 5·3) days, with the second long-lived phase having a median half-life of long-lived ASCs of 2690 (95% CrI: 1016, 261 
15078) days.  In the PsA-TT-002 study, the key difference between antibody kinetics when investigated using the two 262 
assays was the greater proportion of the short-lived phase for the IgG ELISA assay, estimated as 99·1% (95% CrI: 263 
98·5%, 99·5%).  264 
In the PsA-TT-003 study, only data from the first year of longitudinal follow-up was available for model fitting.  The 265 
posterior estimates of the half-life of long-lived ASCs from the PsA-TT-002 study were therefore used as prior 266 
information for the PsA-TT-003 study.  For the long-lived phase of the antibody response the half-life of ASCs 267 
contributing to bactericidal activity was estimated as 6007 (95% CrI: 2826, 14279) days, and the half-life of ASCs 268 
contributing to IgG ELISA measurements was estimated as 2287 (95% CrI: 1380, 4098) days.  For both assays, the 269 
proportion of the antibody response in the second long-lived phase was estimated to be greater in the PsA-TT-003 270 
study than the PsA-TT-002 study. 271 
 272 
Table 2 here  273 
 274 
Age dependency of antibody persistence 275 
The immunogenicity following MenAfriVac vaccination has been well characterised, but determinants of antibody 276 
persistence remain poorly understood23.  Figure 2 shows the dependence of antibody persistence 1 year after 277 
MenAfriVac vaccination on age, and pre- and post-vaccination antibody responses.  The effect of these covariates 278 
are also shown on measured antibody response immediately after vaccination (Supplementary Figure 4), and 1 year 279 
after vaccination (Supplementary Figure 14).  280 
Older age was associated with better persistence when antibody response was measured by both SBA titer (Figure 281 
2A) and ELISA (Figure 2D).  However, in a multivariate analysis age was not significantly associated with antibody 282 
persistence (Table 3).  Greater SBA titers before MenAfriVac vaccination were associated with better antibody 283 
persistence (Figure 2B), but this was not significant in the multivariate analysis (Table 3).  Individuals who had more 284 
immunogenic responses to MenAfriVac when measured by SBA titer also experienced greater reduction in the first 285 
year (Figure 2C), and this was highly significant (p < 0·0001).  Greater IgG ELISA measurements before MenAfriVac 286 
vaccination were associated with better antibody persistence (Figure 2E), and this association was significant (p < 287 
0·0001).  Individuals who had more immunogenic responses to MenAfriVac when measured by IgG ELISA also 288 
experienced greater reduction in the first year (p < 0·0001), although this association was not evident when 289 
examined univariately (Figure 2F). 290 
 291 
Table 3 here 292 
 293 
Predicted vaccine efficacy 294 
Estimates of changing antibody responses over time allow for waning of vaccine efficacy to be estimated, assuming 295 
that antibody correlates with protection.  There are very limited sources of data on meningococcal surrogates of 296 
protection specifically for NmA, however SBA titers ≥ 128 are frequently used as a threshold level15.  Figure 3 shows 297 
an assumed dose-response relationship between SBA titer and vaccine efficacy, corresponding to a profile similar to 298 
an all-or-nothing vaccine.  Based on model predictions we estimate that 20 years after primary vaccination with a 299 
single dose of MenAfriVac, vaccine efficacy will be 70% (95% CrI: 60%, 79%) in the PsA-TT-003 study, and 52% (95% 300 
CrI: 29%, 73%) in the PsA-TT-002 study.  Secondary vaccination with MenAfriVac 10 months after primary 301 
vaccination, was estimated to result in 64% (95% CrI: 40%, 85%) vaccine efficacy after 20 years in the PsA-TT-002 302 
study.  This does not account for the potential role that natural exposure may play in boosting immune responses.    303 
 304 
Discussion 305 
Vaccination with MenAfriVac causes a rapid increase in antibody responses targeting group A N meningitidis, when 306 
measured by either SBA titer or group A-specific IgG ELISA.  This response is characterised in two phases; after 307 
peaking within the first month following vaccination, the first phase of the antibody response decays rapidly within 308 
the first 6 months, so that sustained protection is conferred by the second phase of the immune response.  In 309 
children aged 12-23 months, this long-lived phase of the antibody response is estimated to decay with a half-life of 310 
7·4 (95% CrI: 2·8, 41·3) years when measured by SBA titer, and 4·5 (95% CrI: 2·7, 11·0) years when measured by 311 
ELISA.  In older individuals aged 2-29 years, the long-lived phase was estimated to be longer with a half-life of 16·5 312 
(95% CrI: 7·7, 39·1) years when measured by SBA titer, and 6·3 (95% CrI: 3·8, 11·2) years when measured by ELISA.  313 
These values are comparable with estimated half-lives for anti-tetanus and anti-diphtheria antibody responses of 11-314 
19 years, but decay more rapidly than anti-measles antibodies which demonstrate little reduction over time24.  The 315 
distinctive pattern of bi-phasic waning is consistent with observations following administration of a combination 316 
meningococcal serogroup C and Haemophilus influenza type b vaccine25. 317 
Geometric mean antibody levels in these study populations have been observed to persist above a threshold SBA 318 
titer of 128 for up to 4 years13,14.  However, it is the variation in antibody responses rather than the mean which is 319 
the key determinant of how vaccine efficacy wanes over time.  A key strength of the statistical methods utilised in 320 
this analysis is the ability to characterise the variation in antibody responses in addition to the average behaviour.  321 
For example, consider individual G002_3 in Figure 1B whose rapidly decaying SBA titer may be considered atypical of 322 
the average antibody response.  In some cases in the PsA-TT-002 study, there is an increase in antibody levels 323 
between the samples from years 2 and 5 (Figure 1I-L).  This may be attributable to natural exposure to NmA or cross-324 
reactivity with antibodies to other serogroups or pathogens.  The model does not account for these factors, and the 325 
predictions are only valid in the absence of other exposure.   326 
The availability of data from two independent assays is an advantage, as it provides a consistent picture of how 327 
antibody responses vary over time.  However, some systematic differences between measurements from these 328 
assays highlight some of the limitations that arise when analysing antibody data.  The ELISA assay provides a specific 329 
measurement of IgG molecules that bind to the target antigen, whereas the SBA assay providers a broader 330 
measurement of any functional components of the immune response that contribute to bactericidal activity.  There 331 
were notable differences in the proportion of the antibody response estimated to be long-lived based on 332 
measurements from the two assays, with IgG ELISA levels waning much more rapidly than SBA titers.  A second point 333 
of note is the occurrence of boosting of SBA titers by Hib-TT vaccination (e.g. Figure 1K): this may be attributable to 334 
polyclonal activation of other antibody responses that are cross-reactive on the SBA assay, but not measurable on 335 
the IgG ELISA assay26,27.  Another important point is the different relationship between SBA titers and IgG ELISA levels 336 
observed in the two studies (Supplementary Figure 3): at equal SBA titers individuals in the PsA-TT-003 study have 337 
higher IgG ELISA levels than individuals in the PsA-TT-002 study.  This observation may be due to age effects, or the 338 
higher proportion of samples at long durations of follow-up in the PsA-TT-002 study when IgG ELISA levels have 339 
waned.  The group A strain used in the SBA assays was the standard reference strain (F8238), which is more 340 
representative of a carrier than disease isolate.  It has been argued that assays using strain 3125 provide a more 341 
specific measure of vaccine induced immunity28 but unfortunately, this assay was not used here.  This is an 342 
important limitation but the data presented here are consistent with the regulatory requirements for licensure.  343 
The key determinants of immunogenicity (measured antibody response after vaccination) were age and pre-344 
vaccination antibody response.  For measurements from both assays, high pre-vaccination antibody levels were 345 
associated with greater immunogenicity following MenAfriVac.  In the PsA-TT-002 study of children aged 12-23 346 
months, older age was associated with greater immunogenicity, however in the PsA-TT-003 study of individuals aged 347 
2-29 years, older age was associated with lower immunogenicity (Supplementary Table 3).  This is in contrast to data 348 
following meningococcal serogroup C vaccination where immunogenicity increased with age in children 6-15 years29.  349 
For antibody persistence considered as the percentage of the post-vaccination antibody response remaining after 1 350 
year, there was no significant association with age.  The most important determinant of persistence was 351 
immunogenicity: individuals with the highest antibody responses following MenAfriVac had the greatest 352 
proportional reduction after 1 year.  For antibody levels measured by group A-specific IgG ELISA, greater pre-353 
vaccination antibody levels were associated with better persistence.  The same trend was evident for antibody levels 354 
measured by SBA titer, but was not significant.  Comparing the determinants of immunogenicity (magnitude of 355 
antibody response) and persistence (duration of antibody response), we see that many covariates affect 356 
immunogenicity, notably age and pre-vaccination antibody responses, whereas the key determinant of persistence is 357 
immunogenicity.  358 
Mass immunisation campaigns with MenAfriVac targeting individuals aged 1-29 years in countries in the African 359 
meningitis belt have been followed by substantial reductions in suspected and confirmed N meningitidis group A 360 
cases3,10.  The transition to vaccination of children aged 9-18 months through the routine EPI schedule will lead to a 361 
substantially different profile of immunity in a population.  In the years immediately after a mass immunisation 362 
campaign, most individuals are predicted to still have high levels of vaccine-induced immunogenicity30.  However, 363 
population-level immunity induced via EPI will lead to infants with high levels of immunity due to their recent 364 
vaccination, and adults with lower levels of protection because of the elapsed time since childhood vaccination. 365 
Although based on vaccinees in clinical trials, and not the general population, the estimates provided here can guide 366 
the optimal design of vaccination strategies.   20 years after vaccination with MenAfriVac in participants aged 2-29 367 
years, vaccine efficacy is estimated to be 70% (95% CrI: 60%, 79%).  In children vaccinated at age 12-23 months 368 
(representative of the target EPI population aged 9-18 months), efficacy 20 years after vaccination was estimated to 369 
be substantially lower at 52% (95% CrI: 29%, 73%).  Incorporation of a booster dose of MenAfriVac 10 months after 370 
primary vaccination is estimated to increase efficacy at 20 years to 64% (95% CrI: 40%, 85%).  However, an 371 
alternative strategy would be to delay the primary dose by 10 months until children are older (24-33 months), so 372 
that they mount a more immunogenic response, resulted in an estimated efficacy 20 years later of 63% (95% CrI: 373 
37%, 83%).  However the benefits of such a strategy would need to be weighed against the risks of leaving young 374 
children unvaccinated for longer.  To fully understand the population impact of declining individual protection, 375 
models that incorporate indirect (herd) protection are required12, given the effect of MenAfriVac against carriage as 376 
well as disease30.   377 
 378 
The introduction of MenAfriVac in 2010 was followed by substantial reductions in N meningitidis A cases in the 379 
African meningitis belt.  Characterisation of the kinetics of MenAfriVac-induced antibody responses in individuals will 380 
contribute to understanding the long-term patterns of immunity in populations, enabling us to evaluate and reduce 381 
the risk of future epidemics through adaptive vaccination policies.  382 
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 487 
Tables 488 
Table 1: Overview of epidemiology and immunogenicity in MenAfriVac (PsA-TT) studies.  The PsA-TT-002 data is a 489 
subset of that described by Tapia et al13.  The PsA-TT-003 data is a subset of that described by Diallo et al14.  Age and 490 
duration of follow-up are presented as medians with 95% ranges.  Measurements of immunogenicity are presented 491 
as geometric means with 95% ranges.  The antibody response measured at baseline is denoted by ‘base’; the 492 
response following primary vaccine dose by ‘prim’; and following secondary vaccine dose by ‘sec’.  493 
trial PsA-TT-002 PsA-TT-003 
country Gambia Gambia Gambia Mali Mali Mali Gambia Mali Senegal 
primary 
vaccine 
Hib-TT MenAfriV
ac  
MenAfriV
ac  
Hib-TT MenAfriV
ac  
MenAfriV
ac  
MenAfriV
ac PsA-TT 
MenAfriV
ac PsA-TT 
MenAfriV
ac PsA-TT 
secondary 
vaccine after 
10 months 
 
MenAfriVac 
Hib-TT MenAfriV
ac  
MenAfriV
ac  
Hib-TT MenAfriV
ac  – – – 
N 33 34 30 30 32 34 202 201 201 
age (years) 1·5  
(1·0, 1·9) 
1·4  
(1·0, 1·9) 
1·6  
(1·0, 1·9) 
1·3  
(1·0, 1·9) 
1·3  
(1·0,1·9) 
1·3  
(1·0,1·9) 
15  
(2, 28) 
13  
(3, 25) 
13  
(3, 26) 
gender  
(% female) 
16 (48%) 13 (38%) 15 (50%) 11 (37%) 16 (50%) 19 (56%) 84 (42%) 79 (39%) 87 (43%) 
follow-up 
time (days) 
779  
(777, 807) 
779  
(777, 789) 
780  
(777, 799) 
786  
(770, 805) 
785  
(771, 801) 
783  
(770, 799) 
371  
(366, 380) 
371  
(369, 384) 
391  
(380, 428) 
SBAbase 14  
(2, 1024) 
45  
(2, 3123) 
47  
(2, 2048) 
5  
(2, 1331) 
3  
(2, 659) 
4  
(2, 1204) 
111  
(2, 4096) 
317  
(2, 4096) 
318  
(2, 4096) 
SBAprim 84  
(2, 2560) 
7375  
(1024, 16384) 
7625  
(1510, 42598) 
38  
(2, 3738) 
4008  
(2, 80281) 
4724  
(2, 65536) 
4013  
(512, 16384) 
4225  
(512, 16384) 
6187  
(1024, 32768) 
SBAsec 12299  
(1741, 85197) 
1961  
(256, 32768) 
16845  
(4096, 91750) 
16009  
(1766, 65536) 
1069 
(2, 10035) 
26185  
(8192, 77004) 
– – – 
ELISAbase 
(μg/mL) 
0·13  
(0·1, 5·1) 
0·15  
(0·1, 1·3) 
0·13  
(0·1, 4·6) 
0·13  
(0·1, 0·9) 
0·11  
(0·1, 0·7) 
0·13  
(0·1, 1·0) 
1·9  
(0·1, 26·5) 
3·5  
(0·1, 103·3) 
1·4  
(0·1, 28·6) 
ELISAprim 
(μg/mL) 
0·12  
(0·1, 0·5) 
17·9  
(4·4, 88·6) 
16·9  
(4·6, 55·5) 
0·11  
(0·1, 0·6) 
18·8  
(3·0, 136·9) 
20·5  
(6·0, 210·6) 
48·1  
(9·8, 307·2) 
76·7  
(7·5, 657·5) 
76·2  
(10·3, 639·8) 
ELISAsec 
(μg/mL) 
14·6  
(2·1, 241·7) 
1·3  
(0·1, 24·8) 
50·5  
(4·3, 316·5) 
17·0  
(0·6, 180·6) 
0·9  
(0·1, 10·5) 
87·2  
(17·7, 420·0) – – – 
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 499 
 500 
 501 
 502 
 503 
 504 
 505 
 506 
Table 2: Parameter estimates for the antibody kinetics model.  For each parameter, the distribution of values in the 507 
population was estimated.  The median of this distribution is presented.  Parameters are presented as posterior 508 
medians with 95% credible intervals.  The mean and standard deviation of the parameter distributions are provided 509 
in Supplementary Table 1.  510 
  PsA-TT-002 PsA-TT-003 
description parameter SBA ELISA SBA ELISA 
ASC boost after primary 
MenAfriVac vaccination 
βprim 2502  
(1685, 3984) 
4·4  
(3·3, 6·2) 
1935  
(743, 4693) 
7·0  
(5·3, 12·1) 
ASC boost after secondary 
MenAfriVac vaccination 
βsec 3229  
(2169, 5033) 
12·9  
(8·9, 19·0) 
– – 
ASC boost after Hib-TT vaccination βHib 3·1  
(0·9, 9·0) 
– – – 
half-life of short-lived ASCs (days) ds 3·5  
(2·1, 5·3) 
5·5  
(3·8, 8·3) 
1·5  
(0·7, 3·7) 
9·9  
(5·0, 17·6) 
half-life of long-lived ASCs (days) dl 2690  
(1016, 15078) 
1648  
(969, 4026) 
6007  
(2826, 14279) 
2287  
(1380, 4098) 
half-life of IgG molecules (days) da 15·4  
(12·0, 20·0) 
20·3  
(15·3, 24·7) 
15·5  
(12·4, 20·3) 
30·9  
(21·7, 38·5) 
proportion of short-lived ASCs after 
primary MenAfriVac vaccination 
ρprim 97·0%  
(95·1%, 98·3%) 
99·1%  
(98·5%, 99·5%) 
95·0%  
(85·7%, 98·1%) 
95·7%  
(91·9%, 98·0%) 
proportion of short-lived ASCs after 
secondary MenAfriVac vaccination 
ρsec 97·8%  
(95·9%, 98·8%) 
98·8%  
(98·0%, 99·3%) 
– – 
proportion of short-lived ASCs after 
Hib vaccination 
ρHib 95·8%  
(88·2%, 98·4%) 
– – – 
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 530 
Table 3: Determinants of antibody persistence.  The reduction in antibody response is assumed to be the reduction 531 
from the peak antibody level 4 weeks after MenAfriVac vaccination to the estimated antibody level 1 year after 532 
vaccination.  The association between the percentage reduction and the listed covariates was assessed using logistic 533 
regression.  The association between antibody levels 1 year after MenAfriVac vaccination and the listed covariates 534 
was assessed using linear regression.  The reference is taken to be a Gambian female in the PsA-TT-002 study. 535 
 Serum bactericidal antibody (SBA) Group A-specific IgG ELISA 
 1 year reduction 1 year antibody level 1 year reduction 1 year antibody level 
covariate estimate 
(95% CI) 
p value estimate 
(95% CI) 
p value estimate 
(95% CI) 
p value estimate 
(95% CI) 
p value 
study: PsA-TT-002 
(reference) 
-4·86  
(-6·96, -2·76) 
<0·0001 -0·80  
(-1·39, -0·21) 
0·008 1·75  
(0·08, 3·42) 
0·04 -0·98  
(-0·11, -0·86) 
<0·0001 
study: PsA-TT-003 -1·42  
(-2·61, -0·24) 
0·019 0·39  
(0·06, 0·72) 
0·02 -1·34  
(-2·90, 0·22) 
0·09 0·50  
(0·39, 0·60) 
<0·0001 
country: Mali -0·16  
(-0·54, 0·23) 
0·43 0·19  
(-0·002, 0·24) 
0·054 -0·09  
(-0·51, 0·32) 
0·64 0·006  
(-0·03, 0·045) 
0·78 
country: Senegal -0·09  
(-0·52, 0·35) 
0·70 0·06  
(-0·08, 0·20) 
0·39 -0·04  
(-0·50, 0·41) 
0·85 0·02 
(-0·03, 0·07) 
0·41 
age: PsA-TT-002 -0·28  
(-0·84, 0·28) 
0·32 0·008  
(-0·14, 0·16) 
0·92 -0·46  
(-1·13, 0·22) 
0·19 0·14  
(0·09, 0·19) 
<0·0001 
age: PsA-TT-003 0·29  
(-0·27, 0·85) 
0·31 -0·01  
(-0·16, 0·14) 
0·90 0·42  
(-0·26, 1·10) 
0·22 -0·12  
(-0·17, -0·07) 
<0·0001 
log10(SBAbase) -0·09  
(-0·25, 0·05) 
0·20 0·04  
(-0·009, 0·09) 
0·11 – – – – 
log10(SBApeak) 1·81  
(1·29, 2·33) 
< 0·0001 0·93  
(0·79, 1·07) 
<0·0001 – – – – 
log10(ELISAbase) – – – – -0·75  
(-1·11, -0·40) 
<0·0001 0·23  
(0·19, 0·26) 
<0·0001 
log10(ELISApeak) – – – – 0·73  
(0·31, 1·14) 
0·0006 0·78  
(0·74, 0·82) 
<0·0001 
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Figures 552 
 553 
Figure 1: Antibody kinetics following MenAfriVac vaccination.  (A-H) Antibody kinetics in a subset of 8/797 554 
individuals selected for illustrative purposes.  Data on measured IgG ELISA levels are represented using points, and 555 
SBA titers are represented using intervals.  Solid lines denote the median model predicted antibody level over time, 556 
and the shaded regions denote the 95% credible intervals of the model predictions.  (I-L) Geometric mean antibody 557 
levels in the population.  Shaded regions represent the 95% confidence intervals of the model predicted geometric 558 
mean antibody levels, calculated using a Student’s t-test.  Data points represent geometric mean antibody level as 559 
reported in Tapia et al13 and Diallo et al14.  (M-P) Proportion of individuals with antibody levels greater than specified 560 
thresholds.  Solid lines represent a threshold SBA titer of 128, which corresponds to IgG ELISA level of 2 μg/mL.  561 
Dashed lines represent a threshold SBA titer of 1024, which corresponds to IgG ELISA level of 8·9 μg/mL. 562 
 563 
 564 
 565 
 566 
 567 
Figure 2: Determinants of antibody persistence.  The percentage reduction from the peak antibody level measured 568 
4 weeks after vaccination to the estimated antibody level 1 year after vaccination is shown.  (A) Association between 569 
age and percentage reduction in SBA titer 1 year after MenAfriVac.  (B) Association between pre-vaccination SBA 570 
titer and percentage reduction in SBA titer 1 year after MenAfriVac.  (C) Association between post-vaccination SBA 571 
titer and percentage reduction in SBA titer 1 year after MenAfriVac.  (D) Association between age and percentage 572 
reduction in IgG ELISA 1 year after MenAfriVac.  (E) Association between pre-vaccination IgG ELISA and percentage 573 
reduction in IgG ELISA 1 year after MenAfriVac.  (F) Association between post-vaccination IgG ELISA and percentage 574 
reduction in SBA titer 1 year after MenAfriVac.  The black lines show univariate associations estimated from logistic 575 
regression models.  576 
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 581 
 582 
 583 
Figure 3: Predicted vaccine efficacy based on modelled SBA titers.  (A-C) Model predicted efficacy against infection 584 
over a 20 year time horizon for different vaccination schedules in the PsA-TT-002 study.  (D) Model predicted 585 
efficacy against infection in the PsA-TT-003 study.  Solid lines denote the median model prediction and the dark and 586 
light shaded regions represent the 50% and 95% credible intervals of the model prediction.  (E) Assumed dose-587 
response relationship corresponding to a threshold SBA titer for protection of Abprot = 128, and shape parameter α = 588 
4. 589 
 590 
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Supplementary files 598 
Supplementary methods file: Details of statistical model of antibody kinetics. 599 
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